ArticleJournal of cancer research and clinical oncology2025
Effect of gamma knife dose rate and tumor-specific factors on treatment outcomes in brain metastases: insights from a cohort study.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to investigate the influence of Gamma Knife dose rate on treatment outcomes, in conjunction with tumor-specific factors of composition, size, and primary tumor location.
methodsThis retrospective cohort study analyzed 173 patients with 451 brain metastases treated between 2011 and 2015. Radiosurgery was performed using the Leksell Gamma Knife System, with dose rates categorized into four groups based on cobalt-60 decay: 2.9-2.7, 2.7-2.5, 2.5-2.3, and 2.3-2.1 Gy/min. Tumors were further classified according to dose rate into a simplified high/low classification (cutoff: 2.5 Gy/min) for clinical applicability. The Response Assessment in Neuro-Oncology Brain Metastases Group (RANO-BM) criteria were employed to evaluate treatment response. Statistical analyses were conducted to assess associations between dose rate, tumor characteristics, and outcomes.
resultsNo significant association was identified between dose rates and treatment response (p = 0.35), indicating effective tumor control even at lower dose rates. Tumor composition and size had a significant impact on outcomes; cystic tumors demonstrated poorer responses compared to solid tumors, and larger tumors exhibited reduced efficacy. Specific primary tumor sites, particularly renal cell carcinoma and malignant melanoma, were linked to less favorable responses, confirming their radioresistant characteristics.
conclusionThis study highlights that dose rate does not significantly impact treatment outcomes in Gamma Knife radiosurgery for brain metastases, indicating that effective tumor control can be achieved even at lower dose rates. These findings provide reassurance regarding the efficacy of treatments utilizing decaying cobalt-60 sources and highlight the importance of patient- and tumor-specific factors in predicting radiosurgical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.